Patrick D.
- Country
- France
- Department
- Centre de Coordination de Cancérologie
Research Overview
- Randomized Phase II-III Trial of Maintenance Pembrolizumab ± Pemetrexed Versus Observation ± Pemetrexed in Stage IV Non-Small Cell Lung Cancer Post-Induction Therapy
- Phase 3 Evaluation of Zimberelimab and Domvanalimab Versus Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
- Efficacy and Safety of Lorlatinib Monotherapy in Advanced ROS1-Positive Non-Small Cell Lung Cancer Post First-Line TKI Failure
Data & Insights
Has run more than one trial at 68 of 155 partner sites.
Specializations
Lung Cancer Expertise
This investigator specializes in the treatment of non-small cell lung cancer (NSCLC), with particular focus on both squamous and non-squamous variants.
- Advanced NSCLC management
- Metastatic disease treatment
- Stage IV lung cancer interventions
The investigator's work encompasses comprehensive treatment approaches for various stages of lung cancer progression.
Immunotherapy Applications
The investigator has developed expertise in immunotherapeutic approaches, particularly focusing on treatments involving pembrolizumab and novel immunotherapy combinations.
- Targeted immunotherapy protocols
- Combination therapy strategies
- Novel immunological agents
Their work explores innovative immunotherapy combinations for enhanced treatment outcomes.
Therapeutic Innovation
The investigator explores maintenance therapy strategies using various therapeutic agents including olaparib and pemetrexed for lung cancer treatment.
- Maintenance therapy optimization
- First-line treatment protocols
- Progressive disease management
Their research focuses on developing effective therapeutic combinations for advanced lung cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.